Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Foster

Showing results (1351-1360 of 1,472) with videos related to

Pageof 148
Sort By:
Lancet (London, England)|June 8, 2014
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trialIra M Jacobson, Gregory J Dore, Graham R Foster, et al.
BMC Public Health|December 19, 2023
HepFREEPak: protocol for a multi-centre, prospective observational study examining efficacy and impact of current therapies for the treatment of hepatitis C in Pakistan and reporting resistance to antiviral drugs: study protocolAmbreen Arif, Aliya Hasnain, Auj Chaudhry, et al.
Infection and Immunity|November 28, 2025
A retrospectively registered pilot randomized controlled trial of postbiotic administration during antibiotic treatment increases microbiome diversity and enriches health-associated taxaJonas Schluter, William Jogia, Fanny Matheis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2010
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancerDaniel J Sargent, Silvia Marsoni, Genevieve Monges, et al.
Diabetologia|February 25, 2022
Endothelial glycocalyx is damaged in diabetic cardiomyopathy: angiopoietin 1 restores glycocalyx and improves diastolic function in miceYan Qiu, Stanley Buffonge, Raina Ramnath, et al.
Clinical Pharmacokinetics|February 1, 2015
Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK StatementSalmaan Kanji, Meghan Hayes, Adam Ling, et al.
The New England Journal of Medicine|January 17, 2014
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1Kris V Kowdley, Eric Lawitz, Fred Poordad, et al.
Journal of Viral Hepatitis|May 21, 2019
Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6Eric Lawitz, Edward Gane, Jordan J Feld, et al.
The Journal of Clinical Investigation|January 9, 2018
Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuationLaura Rivino, Nina Le Bert, Upkar S Gill, et al.
Ecological Applications : a Publication of the Ecological Society of America|October 19, 2016
Nonnative forest insects and pathogens in the United States: Impacts and policy optionsGary M Lovett, Marissa Weiss, Andrew M Liebhold, et al.
Pageof 148

Showing results (1351-1360 of 1,472) with videos related to

Sort By:
Pageof 148
Lancet (London, England)|June 8, 2014
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trialIra M Jacobson, Gregory J Dore, Graham R Foster, et al.
BMC Public Health|December 19, 2023
HepFREEPak: protocol for a multi-centre, prospective observational study examining efficacy and impact of current therapies for the treatment of hepatitis C in Pakistan and reporting resistance to antiviral drugs: study protocolAmbreen Arif, Aliya Hasnain, Auj Chaudhry, et al.
Infection and Immunity|November 28, 2025
A retrospectively registered pilot randomized controlled trial of postbiotic administration during antibiotic treatment increases microbiome diversity and enriches health-associated taxaJonas Schluter, William Jogia, Fanny Matheis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2010
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancerDaniel J Sargent, Silvia Marsoni, Genevieve Monges, et al.
Diabetologia|February 25, 2022
Endothelial glycocalyx is damaged in diabetic cardiomyopathy: angiopoietin 1 restores glycocalyx and improves diastolic function in miceYan Qiu, Stanley Buffonge, Raina Ramnath, et al.
Clinical Pharmacokinetics|February 1, 2015
Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK StatementSalmaan Kanji, Meghan Hayes, Adam Ling, et al.
The New England Journal of Medicine|January 17, 2014
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1Kris V Kowdley, Eric Lawitz, Fred Poordad, et al.
Journal of Viral Hepatitis|May 21, 2019
Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6Eric Lawitz, Edward Gane, Jordan J Feld, et al.
The Journal of Clinical Investigation|January 9, 2018
Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuationLaura Rivino, Nina Le Bert, Upkar S Gill, et al.
Ecological Applications : a Publication of the Ecological Society of America|October 19, 2016
Nonnative forest insects and pathogens in the United States: Impacts and policy optionsGary M Lovett, Marissa Weiss, Andrew M Liebhold, et al.
Pageof 148